THCV: a natural cannabinoid tolerated only below 0.3%
THCV, or tetrahydrocannabivarin, is a natural hemp cannabinoid with the structure of THC and a side chain of 3 carbons where THC has 5. In France, the ANSM keeps it off the narcotics list only while its content does not exceed 0.3%. Human data are scarce: four small trials, with 10 to 62 participants.
Key takeaways
- THCV is a "varin": the plant builds it from divarinic acid, where THC starts from olivetolic acid.
- European hemp holds little of it; the high levels come mostly from cannabis populations of Asia and Africa.
- It blocks or activates the CB1 receptor depending on dose and model, and a 2023 trial recorded THC-like effects at 100 and 200 mg.
- In France, THCV and its acid form have been narcotics since June 2024 once each exceeds 0.3%.
- In the 2023 trial, 78 of 79 urine drug screens were positive for THC.
Definition: a short-chain THC
THCV has the same skeleton as THC with a shorter side chain: three carbons (a propyl group) where THC has five (a pentyl group). Chemists call these short-chain cannabinoids "varins", among them THCV, CBDV and CBGV. A 2021 review in Frontiers in Pharmacology notes that their precursor, cannabigerovarinic acid (CBGVA), is made from divarinic acid. The plant's synthases convert it into THCVA, which heat turns into THCV.
Chain length determines how the molecule fits into cannabinoid receptors. At the other end of the series sits THCP, with seven carbons, described on our page on THCP; the page on CBDV covers the varin of CBD.
Where is THCV found?
Most hemp grown in Europe contains very little. A 2022 study of Croatian industrial hemp inflorescences detected no THCVA in its extracts. In 2004, an analysis of 157 cannabis populations found that plants relatively rich in THCV or CBDV were common only in the authors' "indica" group. That group consists mainly of drug-type cannabis from Asia and Africa and leaves out European farm hemp.
Breeders have since developed THCV-rich varieties, as they did for CBG. A product claiming a high THCV content therefore comes from genetics selected for it or contains added purified THCV. In both cases its certificate of analysis should show the measured level, and our guide to reading a certificate of analysis explains where to look.
Pharmacology: an effect that depends on dose
Roger Pertwee's review, published in 2008 in the British Journal of Pharmacology, remains the reference. It describes THCV as blocking CB1 receptor agonists in vitro and, in animals, behaving "either as a CB1 antagonist or, at higher doses, as a CB1 receptor agonist". In vitro, it is also a potent partial agonist at the CB2 receptor.
In plain terms, a low dose of THCV would damp down activation of CB1, the receptor THC targets, and a high dose would activate it. These findings come from cells and animals, and they say nothing about the effect of a given dose in humans.
What human trials show
Four controlled trials are in print, all of them small; two were conducted with cannabis companies.
| Trial | Participants | Dose | Main result |
|---|---|---|---|
| Tudge et al., 2015 | 20 healthy volunteers | 10 mg, single dose | Subjective ratings unchanged; stronger brain responses on MRI |
| Englund et al., 2016 | 10 men | 10 mg a day, 5 days | Indistinguishable from placebo; THC injected afterwards felt weaker to 9 out of 10 |
| Jadoon et al., 2016 | 62 adults with type 2 diabetes | 5 mg twice a day, 13 weeks | Primary endpoint (HDL cholesterol) unchanged |
| Peters et al., 2023 | 21 healthy adults | Δ⁸-THCV, 12.5 to 200 mg | THC-like effects felt at 100 and 200 mg |
At King's College London, Englund and colleagues gave 10 mg of THCV a day for five days, followed by 1 mg of THC intravenously. Taken alone, THCV could not be told apart from placebo. It reduced some effects of THC, such as the faster heart rate, and amplified others, such as memory intrusions. Given the sample size, the authors ask readers to treat these results with caution.
Jadoon and colleagues ran their trial with GW Pharmaceuticals on 62 people. HDL cholesterol, the primary endpoint, did not change. Among the secondary endpoints, fasting glucose dropped 1.2 mmol/l more than on placebo. A pilot trial of this size justifies no promise, and no THCV medicine is authorised. Epidyolex, the only authorised cannabidiol medicine, contains CBD and no THCV.
Peters and colleagues, researchers at Canopy Growth, tested Δ⁸-THCV, an isomer, in single ascending doses. Most adverse events were mild, the most common being euphoric mood. At 100 and 200 mg, participants said they could "feel a drug effect".
Legal status in France: the 0.3% threshold
As of 3 June 2024, the ANSM, the French medicines agency, classified as narcotics several cannabinoids built on the benzo[c]chromene core, the core of THC, HHC and THCP among them. An amending decision dated the same day and announced on 4 June went on to exclude THCV and THCVA "provided that their content does not exceed 0.3% each". The agency's stated aim was to leave aside the traces found in industrial hemp.
In practice, small natural amounts of THCV in a flower or an oil are tolerated, while an enriched product above 0.3% comes under the narcotics rules. The product must also respect the 0.30% Δ⁹-THC cap set by the order of 30 December 2021. How neighbouring molecules were classified is traced in our article on HHC.
Products meant to be swallowed are also subject to the EU novel food regime, which covers all cannabinoid extracts, as our overview of CBD regulation in 2026 explains.
THCV and drug testing
For drivers, this is the point that matters most. In the Peters trial, 78 of 79 urine drug screens taken 8 hours after a dose of Δ⁸-THCV were positive for THC. The authors conclude that a THCV product taken by mouth can turn a THC drug test positive. The tests used in France are described in our guide to CBD and drug testing.
Frequently asked questions
In a 2016 trial, 10 mg a day could not be distinguished from placebo. In a 2023 trial, participants given 100 and 200 mg of Δ⁸-THCV felt a mild THC-like effect, with no measured impairment.
Yes, as long as the product contains no more than 0.3%. Above that, the ANSM decision of June 2024 makes it a narcotic, and the same goes for its acid form, THCVA.
THCV's side chain has 3 carbons, THC's has 5. That changes how the molecule acts on the CB1 receptor, which THCV blocks or activates depending on the dose.
Yes. In the 2023 trial, 78 of 79 urine tests were positive for THC after an oral dose of Δ⁸-THCV, and French roadside tests screen for THC.
European hemp produces very little of it. High levels come from selected genetics, and a product enriched above 0.3% is banned.
Written by the Phytogrammes team
Each journal article draws on cited primary sources: ANSM, EFSA, EUR-Lex and peer-reviewed publications. Product profiles are distinguished from documented laboratory results. Our approach.
Article published on . CBD is not a medicine.